May 14, 2026
China’s Pharmaceutical Weapon
This article was originally published in The National Interest.
This week’s Donald Trump–Xi Jinping summit in Beijing will not lack for contested business. Iran, Taiwan, AI, tariffs, and critical minerals will each compete for time on the agenda, and each will dominate the post-summit coverage. One item less likely to get airtime, however, is one with a direct impact on American lives: the dependence of the US pharmaceutical and biotechnology sector on Chinese inputs, and the leverage that dependence already hands Beijing.
Until SAPIR is extended to biologically derived drugs, until the FDA clears the bovine pathway, and until at least one American-owned heparin manufacturer operates on US soil, every dialysis shift in this country proceeds on the assumption that Beijing will not exercise leverage it already holds.
Heparin is the cleanest illustration. The drug is the blood thinner of record across American medicine—present in nearly every hemodialysis session, every major cardiac procedure, the standard treatment for deep-vein thrombosis and pulmonary embolism, and routine ICU protocols. Most of the US dialysis population—roughly 550,000 patients—have no clinical substitute available to them. The raw material is porcine intestinal mucosa, collected from thousands of small village workshops concentrated in China’s Shandong Province.
Read the full article in The National Interest.
More from CNAS
-
Thanks to Trump, Russia’s Own ‘Pivot to Asia’ Is Bearing Fruit
Commentary
If Washington wants to maintain its strategic position in Southeast Asia, it will need to do more than compete with China. It will also need to avoid handing Russia opportunit...
By Derek Grossman
-
Navigating the Currents: Sri Lanka’s National Security Debate in the New Indian Ocean Order
Commentary
Sri Lanka’s national security debate in 2026 is ultimately between whether the country can break from the institutional pressures that have constrained previous reform attempt...
By Keerthi Martyn
-
XI Jinping Looking to Bring North Korea Back Into China’s Orbit: Analyst
Video
Duyeon Kim, Adjunct Senior Fellow at the Center for a New American Security, says her sources have informed her that Beijing is unhappy with Pyongyang’s growing relationship w...
By Duyeon Kim
-
Does the Quad Still Matter?
Commentary
Under the second Trump administration, some analysts have expressed growing pessimism about the group’s effectiveness, given the president’s apparent lack of interest in atten...
By Lisa Curtis
